Logo image of PCRX.CA

PHARMACORP RX INC (PCRX.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:PCRX - CA71714X1050 - Common Stock

0.46 CAD
0 (0%)
Last: 12/30/2025, 7:00:00 PM
Fundamental Rating

2

Overall PCRX gets a fundamental rating of 2 out of 10. We evaluated PCRX against 17 industry peers in the Consumer Staples Distribution & Retail industry. While PCRX has a great health rating, there are worries on its profitability. PCRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PCRX had negative earnings in the past year.
PCRX had a positive operating cash flow in the past year.
PCRX.CA Yearly Net Income VS EBIT VS OCF VS FCFPCRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -500K -1M -1.5M

1.2 Ratios

PCRX has a Return On Assets of 0.48%. This is in the lower half of the industry: PCRX underperforms 70.59% of its industry peers.
PCRX has a worse Return On Equity (0.63%) than 70.59% of its industry peers.
Industry RankSector Rank
ROA 0.48%
ROE 0.63%
ROIC N/A
ROA(3y)-14.02%
ROA(5y)N/A
ROE(3y)-14.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PCRX.CA Yearly ROA, ROE, ROICPCRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

PCRX has a worse Profit Margin (1.08%) than 70.59% of its industry peers.
Looking at the Gross Margin, with a value of 39.77%, PCRX belongs to the top of the industry, outperforming 82.35% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 1.08%
GM 39.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCRX.CA Yearly Profit, Operating, Gross MarginsPCRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 20 -20

More info and screens

7

2. Health

2.1 Basic Checks

PCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PCRX has been increased compared to 1 year ago.
Compared to 1 year ago, PCRX has a worse debt to assets ratio.
PCRX.CA Yearly Shares OutstandingPCRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M 80M 100M
PCRX.CA Yearly Total Debt VS Total AssetsPCRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

PCRX has an Altman-Z score of 5.42. This indicates that PCRX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.42, PCRX belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
The Debt to FCF ratio of PCRX is 2.81, which is a good value as it means it would take PCRX, 2.81 years of fcf income to pay off all of its debts.
PCRX has a Debt to FCF ratio of 2.81. This is amongst the best in the industry. PCRX outperforms 100.00% of its industry peers.
PCRX has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.13, PCRX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 2.81
Altman-Z 5.42
ROIC/WACCN/A
WACC7.79%
PCRX.CA Yearly LT Debt VS Equity VS FCFPCRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

PCRX has a Current Ratio of 2.53. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
PCRX's Current ratio of 2.53 is amongst the best of the industry. PCRX outperforms 100.00% of its industry peers.
A Quick Ratio of 1.79 indicates that PCRX should not have too much problems paying its short term obligations.
PCRX has a better Quick ratio (1.79) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.53
Quick Ratio 1.79
PCRX.CA Yearly Current Assets VS Current LiabilitesPCRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.98%.
EPS 1Y (TTM)-5.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%334.83%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCRX.CA Yearly Revenue VS EstimatesPCRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 1M 2M 3M 4M 5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
PCRX.CA Price Earnings VS Forward Price EarningsPCRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PCRX is valued expensively inside the industry as 88.24% of the companies are valued cheaper.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a slightly more expensive valuation: PCRX is more expensive than 70.59% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 52.02
EV/EBITDA 145.13
PCRX.CA Per share dataPCRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.05 0.1 0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PCRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PHARMACORP RX INC

TSX-V:PCRX (12/30/2025, 7:00:00 PM)

0.46

0 (0%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)11-29 2025-11-29
Earnings (Next)04-20 2026-04-20
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners10.67%
Ins Owner ChangeN/A
Market Cap80.08M
Revenue(TTM)17.60M
Net Income(TTM)189.60K
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.55
P/FCF 52.02
P/OCF 49.81
P/B 2.67
P/tB 10.01
EV/EBITDA 145.13
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY1.92%
OCF(TTM)0.01
OCFY2.01%
SpS0.1
BVpS0.17
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.48%
ROE 0.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1.08%
GM 39.77%
FCFM 8.74%
ROA(3y)-14.02%
ROA(5y)N/A
ROE(3y)-14.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 2.81
Debt/EBITDA 7
Cap/Depr 8.65%
Cap/Sales 0.39%
Interest Coverage N/A
Cash Conversion 293.95%
Profit Quality 811.87%
Current Ratio 2.53
Quick Ratio 1.79
Altman-Z 5.42
F-Score6
WACC7.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.14%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%334.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-174.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y122.73%
FCF growth 3Y518.15%
FCF growth 5YN/A
OCF growth 1Y124.06%
OCF growth 3Y529.96%
OCF growth 5YN/A

PHARMACORP RX INC / PCRX.CA FAQ

What is the ChartMill fundamental rating of PHARMACORP RX INC (PCRX.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PCRX.CA.


What is the valuation status of PHARMACORP RX INC (PCRX.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to PHARMACORP RX INC (PCRX.CA). This can be considered as Overvalued.


How profitable is PHARMACORP RX INC (PCRX.CA) stock?

PHARMACORP RX INC (PCRX.CA) has a profitability rating of 1 / 10.


What is the financial health of PHARMACORP RX INC (PCRX.CA) stock?

The financial health rating of PHARMACORP RX INC (PCRX.CA) is 7 / 10.